- Motley Fool•13 hours ago
The exciting race to develop the first CAR-T therapy recently took some unexpected twists for Juno Therapeutics, bluebird bio, and Kite Pharma.
- Investor's Business Daily•yesterday
Bluebird stock rocketed Thursday and Celgene is seeing life post-Revlimid patent cliff on a new multiple myeloma drug.
CELG : Summary for Celgene Corporation - Yahoo Finance
Celgene Corporation (CELG)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||117.40 x 400|
|Ask||117.63 x 200|
|Day's Range||117.23 - 119.39|
|52 Week Range||93.05 - 127.00|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||44.68|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|